Abstract:Arginine‐coated thiolated pluronic SNEDDS of Rifampicin are successfully formulated and characterized. Size of the SNEDDS is 148.4 nm having PDI of 0.3. Drug dissolution shows 80% sustained release in 72 h. SNEDDS are capable to kill T.B strains at low dose of drug. SNEDDS are found to be safe and compatible to blood. SNEDDS uptake is maximum in targeted cells. The study aimed to develop thiolated pluronic‐based self‐emulsifying drug delivery system (SNEDDS) targeted delivery of Rifampicin coated by arginine for enhanced drug loading, mucoadhesion, muco penetration, site‐specific delivery, stabilized delivery against intracellular mycobacterium tuberculosis (M. tb), decreased bacterial burden and production by intracellular targeting. Oleic oil, PEG 200 and Tween 80 are selected as oil, co‐surfactant and surfactant based on solubilizing capacity and pseudo ternary diagram region. Coating of thiolated polymer on SNEDDS with ligand arginine (Arg‐Th‐F407 SNEDDDS) decreased bacterial burden and production by intracellular targeting in macrophages. Formulation are evaluated through scanning electron microscope (SEM), EDAX analysis, diffraction laser scattering (DLS), Fourier transform infrared (FTIR) spectroscopy, and thermal analysis (DSC & TGA). Hydrodynamic diameter of thiolated polymeric SNEDDS (Th‐F407 SNEDDS) and Arg‐Th‐F407 SNEDDS is observed to be 148.4 and 188.5 nm with low PDI of 0.4 and 0.3, respectively. Invitro drug release study from Arg‐Th‐F407 SNEDDS indicates 80% sustained release in 72 h under controlled conditions. Arg‐Th‐F407 SNEDDDS shows excellent capability of killing M.tb strains in macrophages even at low dose as compared to traditional rifampicin (RIF) and is found biocompatible, non‐cytotoxic, and hemocompatible. Therefore, Arg‐Th‐F407 SNEDDDS of RIF proved ideal for targeting and treating M.tb strains within macrophages.

Promising Chitosan-Coated Alginate-Tween 80 Nanoparticles as Rifampicin Coadministered Ascorbic Acid Delivery Carrier Against Mycobacterium tuberculosis

An aerosol nanocomposite microparticle formulation using rifampicin-cyclodextrin inclusion complexes for the treatment of pulmonary diseases

Quantification of rifampicin loaded into inhaled polymeric nanoparticles by reversed phase high-performance liquid chromatography in pulmonary nonphagocytic cellular uptake

Rifampicin‐Loaded Nano‐In‐Microparticles (Trojan Particles) As A Pulmonary Delivery System For Tuberculosis Treatment

Drug-in-cyclodextrin-in-polymeric nanoparticles: A promising strategy for rifampicin administration

Enhanced rifampicin delivery to alveolar macrophages by solid lipid nanoparticles

Mannose-Decorated Solid-Lipid Nanoparticles for Alveolar Macrophage Targeted Delivery of Rifampicin

Mucoadhesive Polymer Tangeretin Loaded Chitosan Nanoparticles to Combat the Resistance of Mycobacterium Tuberculosis

Sodium Hyaluronate Nanocomposite Respirable Microparticles to Tackle Antibiotic Resistance with Potential Application in Treatment of Mycobacterial Pulmonary Infections

Responding to Hitch in Fighting Mycobacterium Tuberculosis Through Arginine Multi Functionalized Mucoadhesive SNEDDS of Rifampicin

Antimicrobial peptides grafted onto the surface of N-acetylcysteine-chitosan nanoparticles can revitalize drugs against clinical isolates of Mycobacterium tuberculosis

Genipin-crosslinked Carboxymethyl Chitosan Nanogel for Lung-Targeted Delivery of Isoniazid and Rifampin.

Dihydroartemisinin-Loaded Chitosan Nanoparticles Inhibit the Rifampicin-Resistant Mycobacterium tuberculosis by Disrupting the Cell Wall

Novel Approach for Transdermal Delivery of Rifampicin to Induce Synergistic Antimycobacterial Effects Against Cutaneous and Systemic Tuberculosis Using a Cationic Nanoemulsion Gel

Preparation and characterization of rifampicin-PLGA microspheres/sodium alginate in situ gel combination delivery system.

Muco-adhesive Chitosan-Coated Polyphenol Nanoparticle for Treatment of Infectious Acute Pneumonia Through Sustained Pulmonary Delivery of Polymyxin B

Rifabutin-loaded solid lipid nanoparticles for inhaled antitubercular therapy: Physicochemical and in vitro studies

A novel synergistic enzyme-antibiotic therapy with immobilization of mycobacteriophage Lysin B enzyme onto Rif@UiO-66 nanocomposite for enhanced inhaled anti-TB therapy; Nanoenzybiotics approach

Optimization of Polylactide-Co-Glycolide-Rifampicin Nanoparticle Synthesis, In Vitro Study of Mucoadhesion and Drug Release

Microencapsulated Isoniazid-Loaded Metal-Organic Frameworks for Pulmonary Administration of Antituberculosis Drugs

Lower Cytotoxicity, High Stability, and Long-Term Antibacterial Activity of a Poly(methacrylic Acid)/isoniazid/rifampin Nanogel Against Multidrug-Resistant Intestinal Mycobacterium Tuberculosis.